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Efficacy of Integrating CBT for Mental Health Care into Substance Abuse 
Treatment in Patients with Comorbid Disorders of Substance Abuse and Mental 
Illness
Purpose
The purpose of this DNP project is to identify the 
effectiveness of Cognitive Behavioral Therapy 
(CBT) to treat Substance Use Disorder (SUD) and 
mental health disorders in an integrated manner, 
instead of independently when applying current 
treatment as usual.
Specific Aims
• Determine opiate use and co-morbid disorder 
percentages in psychiatric patients;
• Compare overdoses, substance-related incidents 
and hospitalizations before and after CBT;
• Compare the number of urine-free drug screens 
before, during and after CBT;
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Background
• Comorbid disorders comprise any two or more 
substance use disorders (SUDs) and mental illness 
and are recognized in the DSM-V (American 
Psychiatric Association, 2013).
• In 2014, approximately 7.9 million adults had a 
comorbid disorder (SAMSHA, 1, 2015).
• Comorbid disorders often occur together, while 
symptoms can overlap. This overlap can be 
functional. For example, mental illness disorders can 
make the co-occurrence of SUDs more likely (Kessler, 
2004).
• SUD and mental illness are likely to occur together, 
but are often treated separately (Kessler, 2004).
• Many individuals may benefit from a dual diagnosis 
treatment, but there are not many resources and 
treatment centers available for such a therapy.
• Interviews with Dual-Diagnosis patients reveal that 
patients perceive their mental health diagnosis and 




• Retrospective chart review of adult patients
Setting
• Ultimate Treatment Center in Ashland, KY
Study Duration
• January 10th, 2020 – October 1st, 2020
Study Population
• Adult patients ages 18+ with comorbid 
disorders: SUD and mental illness
IRB
• UTHSC Institutional Review Board has deemed 
the project as exempt.
Procedures
•30 charts of patients 18 years or older with co-
morbid disorders were reviewed, with the goal of 
identifying the impact of collaborative therapy 
including CBT and pharmacotherapy.
•Participants who did not speak English, younger 
than 18 years old, did not have a diagnosis of 
mental illness or received MAT, were excluded 
from the study.
• Sociodemographic variables: age, education, 
ethnicity, employment, primary language, marital 
status, and insurance; clinical variables: diagnosis 
of substance disorder and mental illness, such as 
depression, anxiety disorders, mood disorders, 
schizophrenia, and other psychiatric disorders;
•Data were taken from electronic health records 
from  January 10 and October 1, 2020.
•Descriptive data was used to analyze the data.
Results
• Most participants were between 30 – 39 or 40 – 49 years old. More women 
than men participated. Among 18 – 29-year-olds, only males took part, 
while among the 50 – 60-year-olds, only women participated.
• Most patients used opiates for more than 10 years; in most cases, patients 
suffered from depression.
• Before CBT, hospital admissions, overdoses and substance-related accidents 
were almost 3 per individual; after therapy, the number was less then 0.25 
per person.
• During and after CBT, the number of opioid-free urine drug screens 
increased three-fold.
Implications for Practice
• Treatment with CBT led to a significantly lower number of 
overdoses, drug-related accidents and hospital admissions; 
therefore, CBT should be considered for the integrated co-
treatment of individuals that have a co-morbidity of a mental 
health disorder and substance use disorder.
• However, there is also a need for more research into specific 
aspects of comorbidity. Does CBT improve other factors 
beyond drug use? What is the long-term potential of CBT? 
Should patients continue to be treated with CBT even after 
their release from the treatment institution?
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